- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07946601
Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Laura Bukavina, MD, MPH, MSc
- Número de teléfono: (216) 444-6043
- Correo electrónico: bukavil2@ccf.org
Copia de seguridad de contactos de estudio
- Nombre: Myra Krnac
- Número de teléfono: (216)444-1047
- Correo electrónico: krnacm@ccf.org
Ubicaciones de estudio
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Cleveland Clinic Foundation
-
Contacto:
- Laura Bukavina, MD, MPH, MSc
- Número de teléfono: (216) 444-6043
- Correo electrónico: bukavil2@ccf.org
-
Investigador principal:
- Laura Bukavina, MD, MPH, MSc
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
- Planned for radical cystectomy with curative intent.
- Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Adequate organ function as defined by standard laboratory criteria.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
- Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
- Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
- Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ctDNA-negative MIBC
There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments. |
Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrence free survival (RFS)
Periodo de tiempo: 2 years
|
RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first. |
2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival (OS)
Periodo de tiempo: at 2 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 2 years
|
|
Overall survival
Periodo de tiempo: at 5 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 5 years
|
|
Rate of pathological complete response (pCR)
Periodo de tiempo: at day 0
|
To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy. |
at day 0
|
|
Rates of surgical morbidity
Periodo de tiempo: up to 4 weeks
|
To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Rates of complications
Periodo de tiempo: up to 4 weeks
|
To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Positive predictive value
Periodo de tiempo: days -42 to 0
|
To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
|
Negative predictive value
Periodo de tiempo: days -42 to 0
|
To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- CASE9826
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
There is not currently an intention or plan to share IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .